Source: RBC
2019 witnessed a considerable growth of pharmaceutical production volume in Russia (by 24.5% in financial terms, reaching 386.7 bln rubles) and an increase in the number of companies with a positive financial result at the end of the year. Of the nearly 600 companies included in the monitoring, only slightly more than a half (50.6%) were profitable in 2018, while in 2019 they accounted for 57.0%.
It should be noted that last year the total net profit for all profitable companies estimated at 78.1 bln rubles. On the other hand, the total volume of losses incurred by the players with the negative financial result reached 3.3 bln.
The top-5 ranking of the most profitable pharmaceutical manufacturers in Russia included:
Methodology: the monitoring included companies with primary OKVED-2 (Russian National Classifier of Economic Activities) codes "21.2: Manufacture of Pharmaceuticals and Medical Materials" and "21.20.1: Manufacture of Pharmaceuticals" with the information on their revenue for 2019, and some manufacturers with other primary OKVED-2 codes (such as Teva Ltd., Takeda Pharmaceuticals LLC, etc.). The sample size was 575 companies.
Source reference:
| Back | Print out |
